Thuresson Po

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

G. Wells, S. Dent, P. Thuresson, 2015, Journal of medical economics.